Mirum Pharmaceuticals, Inc.
MIRM
$43.42
-$0.03-0.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -67.12% | 42.22% | 2.54% | 29.11% | -51.17% |
| Total Depreciation and Amortization | -0.46% | 0.25% | 13.68% | 0.46% | 97.96% |
| Total Amortization of Deferred Charges | -1.89% | 4.18% | -1.69% | 3.76% | -2.92% |
| Total Other Non-Cash Items | 69.41% | -45.84% | 16.59% | -38.00% | 163.85% |
| Change in Net Operating Assets | -150.45% | 519.90% | -103.65% | 391.84% | -31.97% |
| Cash from Operations | -227.21% | 204.76% | -125.00% | 191.54% | 8.80% |
| Capital Expenditure | 88.95% | 76.77% | -5,892.31% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.70% | 75.18% | -- | -- | -106.67% |
| Cash from Investing | 103.55% | 75.20% | -559,261.54% | 99.35% | 98.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 38.23% | -47.02% | 505.06% | -41.45% | -99.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 38.23% | -47.02% | 505.06% | -32.19% | -99.14% |
| Foreign Exchange rate Adjustments | -1,667.05% | 173.95% | -205.31% | 4.63% | 134.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.39% | 85.43% | -519.86% | 198.71% | -386.97% |